EPRX
Income statement / Annual
Last year (2023), Eupraxia Pharmaceuticals Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Eupraxia Pharmaceuticals Inc. Common Stock's net income was -$28.74 M.
See Eupraxia Pharmaceuticals Inc. Common Stock’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$158,378.00 |
$142,577.00 |
$88,174.00 |
$91,686.00 |
$155,724.00 |
$92,126.00 |
$68,139.00 |
| Gross Profit |
-$158,378.00 |
-$142,577.00 |
-$88,174.00 |
-$91,686.00 |
-$155,724.00 |
-$92,126.00 |
-$68,139.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$27.54 M
|
$12.97 M
|
$7.86 M
|
$849,746.00
|
$2.64 M
|
$4.99 M
|
$2.64 M
|
| General & Administrative
Expenses |
$7.28 M
|
$3.99 M
|
$8.89 M
|
$1.27 M
|
$1.53 M
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$296,693.00
|
-$2.24 M
|
-$273,055.00
|
$790,315.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$7.28 M
|
$4.28 M
|
$6.65 M
|
$996,548.00
|
$2.32 M
|
$3.74 M
|
$1.17 M
|
| Other Expenses |
$0.00 |
$0.00 |
-$2.26 M |
$0.00 |
$1,737.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$37.20 M |
$17.25 M |
$14.51 M |
$1.85 M |
$4.97 M |
$8.74 M |
$3.81 M |
| Cost And Expenses |
$37.20 M |
$17.39 M |
$14.60 M |
$1.94 M |
$5.12 M |
$8.83 M |
$3.87 M |
| Interest Income |
$862,969.00 |
$431,799.00 |
$65,728.00 |
$427.00 |
$0.00 |
$809.78 |
$263.38 |
| Interest Expense |
$1.17 M |
$982,856.00 |
$1.30 M |
$1.88 M |
$0.00 |
$104,095.00 |
$42,145.00 |
| Depreciation &
Amortization |
$158,378.00
|
$142,577.00
|
$88,174.00
|
$91,686.00
|
$155,724.00
|
$92,126.00
|
$68,139.00
|
| EBITDA |
-$36.75 M
|
-$23.70 M
|
-$17.85 M
|
-$2.13 M
|
-$6.04 M
|
-$11.76 M
|
-$4.65 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$1.14 M
|
-$1.42 M
|
-$5.96 M
|
-$324,661.00
|
$519,088.00
|
-$2.90 M
|
-$228,507.00
|
| Income Before Tax |
-$38.33 M |
-$17.64 M |
-$18.48 M |
-$3.15 M |
-$5.58 M |
-$10.86 M |
-$3.99 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$48,259.00 |
-$485,291.00 |
-$300,382.00 |
-$10,544.00 |
-$49,688.00 |
-$1.17 M |
-$543,009.00 |
| Net Income |
-$28.74 M |
-$17.16 M |
-$18.18 M |
-$3.14 M |
-$5.53 M |
-$9.69 M |
-$3.45 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.55 |
-0.89 |
-1.28 |
-0.24 |
-0.43 |
-0.75 |
-0.27 |
| EPS Diluted |
-1.55 |
-0.89 |
-1.28 |
-0.24 |
-0.43 |
-0.75 |
-0.27 |
| Weighted Average Shares
Out |
$24.15 M
|
$19.29 M
|
$14.24 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
| Weighted Average Shares
Out Diluted |
$24.15 M
|
$19.29 M
|
$14.24 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
$12.87 M
|
| Link |
|
|
|
|
|
|
|
